Pimicotinib hydrochloride is under clinical development by Abbisko Therapeutics and currently in Phase I for Pancreatic Cancer.

(Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced ...

Pancreatic cancer screening has advanced significantly in recent years. There are now research-based guidelines on screening ...

AMT-676 is under clinical development by Multitude therapeutics and currently in Phase I for Pancreatic Ductal Carcinoma.

More information: Elias Saba et al, Oral bacteria accelerate pancreatic cancer development in mice, Gut (2024). DOI: 10.1136/gutjnl-2023-330941 Provided by Hebrew University of Jerusalem ...

SciSparc (SPRC)announced that MitoCareX Bio, its joint venture with Dr. Alon Silberman, is expanding its research and development efforts into ...

This opens the door to the development of effective new therapies. Pancreatic cancer ranks among the most lethal cancers, with an exceptionally high mortality rate. One of the reasons is the lack ...

(RTTNews) - Immuneering Corp. (IMRX), Tuesday announced positive data update from three arms of its ongoing Phase 2a trial of lead program IMM-1-104 for the treatment of patients with Pancreatic ...